Hypercholesterolemia

"Hypercholesterolemia" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A condition with abnormally high levels of CHOLESTEROL in the blood. It is defined as a cholesterol value exceeding the 95th percentile for the population.

Descriptor ID	D006937
MeSH Number(s)	C18.452.584.500.500.396
Concept/Terms	Hypercholesterolemia Hypercholesterolemia Hypercholesterolemias Elevated Cholesterol Hypercholesteremia Hypercholesteremias

Below are MeSH descriptors whose meaning is more general than "Hypercholesterolemia".

Diseases [C]
Nutritional and Metabolic Diseases [C18]
Metabolic Diseases [C18.452]
Lipid Metabolism Disorders [C18.452.584]
Dyslipidemias [C18.452.584.500]
Hyperlipidemias [C18.452.584.500.500]
Hypercholesterolemia [C18.452.584.500.500.396]

Below are MeSH descriptors whose meaning is related to "Hypercholesterolemia".

Below are MeSH descriptors whose meaning is more specific than "Hypercholesterolemia".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Hypercholesterolemia" by people in this website by year, and whether "Hypercholesterolemia" was a major or minor topic of these publications.

Bar chart showing 139 publications over 34 distinct years, with a maximum of 9 publications in 2015

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1982	0	1	1
1987	0	1	1
1988	2	0	2
1989	1	0	1
1990	1	0	1
1991	3	0	3
1992	4	1	5
1993	2	1	3
1994	1	1	2
1995	1	0	1
1996	3	2	5
1997	5	3	8
1998	0	3	3
1999	2	3	5
2000	3	2	5
2001	4	2	6
2002	2	1	3
2003	5	2	7
2004	3	1	4
2005	3	2	5
2006	1	1	2
2007	3	2	5
2008	3	5	8
2009	2	4	6
2010	2	1	3
2011	1	2	3
2012	2	2	4
2013	4	1	5
2014	5	0	5
2015	5	4	9
2016	6	1	7
2017	5	1	6
2018	3	0	3
2020	1	1	2

Below are the most recent publications written about "Hypercholesterolemia" by people in Profiles.

O'Donnell CJ. Opportunities and Challenges for Polygenic Risk Scores in Prognostication and Prevention of Cardiovascular Disease. JAMA Cardiol. 2020 04 01; 5(4):399-400. PMID: 32049302.

View in: PubMed
Salvia C, Donfrancesco C, Palmieri L, Lo Noce C, Vanuzzo D, Vinceti M, Bargellini A, Borella P, Giampaoli S. [The Health Examination Survey at regional level: the Emilia-Romagna Region (Northern Italy) example]. Epidemiol Prev. 2020 Jan-Feb; 44(1):40-47. PMID: 32374113.

View in: PubMed
Kinsey TL, Stürmer T, Poole C, Rothman KJ, Glynn RJ. Changing predictors of statin initiation in US women over two decades. Pharmacoepidemiol Drug Saf. 2019 03; 28(3):305-314. PMID: 30565779.

View in: PubMed
Sun YV, Damrauer SM, Hui Q, Assimes TL, Ho YL, Natarajan P, Klarin D, Huang J, Lynch J, DuVall SL, Pyarajan S, Honerlaw JP, Gaziano JM, Cho K, Rader DJ, O'Donnell CJ, Tsao PS, Wilson PWF. Effects of Genetic Variants Associated with Familial Hypercholesterolemia on Low-Density Lipoprotein-Cholesterol Levels and Cardiovascular Outcomes in the Million Veteran Program. Circ Genom Precis Med. 2018 12; 11(12). PMID: 31106297.

View in: PubMed
Toth PP, Dwyer JP, Cannon CP, Colhoun HM, Rader DJ, Upadhyay A, Louie MJ, Koren A, Letierce A, Mandel J, Banach M. Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease. Kidney Int. 2018 06; 93(6):1397-1408. PMID: 29526502.

View in: PubMed
Thanassoulis G, Pencina MJ, Sniderman AD. The Benefit Model for Prevention of Cardiovascular Disease: An Opportunity to Harmonize Guidelines. JAMA Cardiol. 2017 11 01; 2(11):1175-1176. PMID: 28793137.

View in: PubMed
Intwala S, Stone NJ, Balady GJ. Low-Density Lipoprotein Measurement Discordance: When 2 Wrongs Lead to the Right Answer-Elevated Lipoprotein (a). JAMA Cardiol. 2017 06 01; 2(6):697-698. PMID: 28355452.

View in: PubMed
Katsiki N, Athyros VG, Mikhailidis DP, Mantzoros C. Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors: Shaping the future after the further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk (FOURIER) trial. Metabolism. 2017 09; 74:43-46. PMID: 28477848.

View in: PubMed
Jamieson L, Evans D, Brennan AT, Moyo F, Spencer D, Mahomed K, Maskew M, Long L, Rosen S, Fox MP. Changes in elevated cholesterol in the era of tenofovir in South Africa: risk factors, clinical management and outcomes. HIV Med. 2017 Sep; 18(8):595-603. PMID: 28332270.

View in: PubMed
Ridker PM, Tardif JC, Amarenco P, Duggan W, Glynn RJ, Jukema JW, Kastelein JJP, Kim AM, Koenig W, Nissen S, Revkin J, Rose LM, Santos RD, Schwartz PF, Shear CL, Yunis C. Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab. N Engl J Med. 2017 04 20; 376(16):1517-1526. PMID: 28304227.

View in: PubMed

People

See all people

Similar Concepts

Top Journals